Full Press Release Details
STOCKHOLM, SE / ACCESS Newswire / September 1, 2026 / Vicore Pharma Holding AB (STO:VICO))(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following upcoming healthcare conferences:
Wells Fargo Healthcare Conference Location: Encore Boston Harbor, Boston, Mass. Format: 1×1 meetings Participation Date: Tuesday, September 8, 2026 Participant: Ahmed Mousa, Chief Executive Officer
Cantor Global Healthcare Conference Location: Waldorf Astoria New York, New York, N.Y. Format: Fireside chat and 1×1 meetings Fireside Chat Date and Time: Friday, September 11, 2026, 9:45-10:15 AM ET Webcast: Link Participant: Ahmed Mousa, Chief Executive Officer
Hans Jeppsson, CFO, +46 70 553 14 65, [email protected]
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com
Attachments Vicore Pharma to Participate in Upcoming Healthcare Conferences